Trial site
Velocity Clinical Research, Providence
East Greenwich, Rhode Island 02818, United StatesNot linked to an institution yet
- 18running trials
- 14closed trials
The trials here
What the 32 trials at this site are about, from their registry records.
- Phase
- Phase 322 trials
- Phase 26 trials
- Phase 42 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Completed14 trials
- Active, not recruiting9 trials
- Recruiting8 trials
- Not yet recruiting1 trial
- Lead sponsor
- Pfizer7 trials
- Amgen5 trials
- Vertex Pharmaceuticals Incorporated4 trials
- Eli Lilly and Company3 trials
- ModernaTX, Inc.2 trials
- and 11 more
Running trials
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144· Phase 3· Amgen· Source
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235· Phase 3· Amgen· Source
Recruiting
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
NCT07500506· Phase 3· Pfizer· Source
Active, not recruiting
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
NCT07496450· Phase 3· ModernaTX, Inc.· Source
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Active, not recruiting
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878· Phase 3· Amgen· Source
Active, not recruiting
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839· Phase 3· Amgen· Source
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466· Phase 3· Pfizer· Source
Active, not recruiting
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079· Phase 4· Currax Pharmaceuticals· Source
Recruiting
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
NCT07546929· Phase 2· Housey Healthcare ULC· Source
Contact: David Fried, MD (principal investigator)
Active, not recruiting
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Recruiting
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141· Phase 3· Pfizer· Source
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242· Phase 3· Pfizer· Source
Active, not recruiting
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479· Phase 2/3· Sun Pharmaceutical Industries, Inc.· Source
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860· Phase 2· Vertex Pharmaceuticals Incorporated· Source
Completed
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
NCT06603623· Phase 2· Biohaven Therapeutics Ltd.· Source
Completed
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935· Phase 2· Carmot Therapeutics, Inc.· Source
Completed
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
NCT06015282· Phase 3· Seqirus· Source
Completed
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
NCT05972174· Phase 1/2· ModernaTX, Inc.· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
NCT05596734· Phase 2· BioNTech SE· Source
Completed
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522· Phase 3· Pfizer· Source
Completed
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
NCT05505734· Phase 3· Bond Avillion 2 Development LP· Source
Completed
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
NCT05477524· Phase 3· Pfizer· Source
Completed
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
NCT05217927· Phase 4· Pfizer· Source
Completed
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
NCT05279313· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· Phase 2· Gilead Sciences· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
NCT03899259· Phase 3· Eli Lilly and Company· Source
Report an error